Clinical Use of Stem Cells for the Treatment of Covid-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-01

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to use the regenerative and repair abilities of stem cells to fight against the harmful effects of the novel coronavirus Covid-19 and therefore develop a treatment strategy. It is known that fatalities from this virus is largely caused by its damage to lungs and other organs. As the disease progresses, these organs fail and lead to mortality. Our hope is that the stem cell transplantation from healthy donors will repair the damage caused by the virus and result in a healthy recovery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

When to Apply to Which Patient in MSC?

NCT05240430

COVID-19 Acute Respiratory Distress Syndrome

UNKNOWN

MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome

NCT04525378

Covid19 ARDS, Human

UNKNOWN PHASE1

Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)

NCT04377334

ARDS COVID-19

UNKNOWN PHASE2

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)

NCT04345601

Sars-CoV2 Acute Respiratory Distress Syndrome COVID-19

COMPLETED PHASE1/PHASE2

Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients

NCT05132972

Covid 19

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction:

The COVID-19 corona virus epidemic has spread from Wuhan, China to the whole world, and has been declared a pandemic by WHO worldwide. In severe patients, ARDS and multiple organ failure can be seen. This condition is associated with cytokine storm in the body. When the virus invades the body, dentric cells can activate macrophages, lymphocytes and natural killer cells. Mesenchymal stem cells (MKH) not only inhibit the abnormal activation of T lymphocytes and macrophages, but also encourage them to differentiate into regulatory T cell subsets (Treg) clusters and anti-inflammatory macrophages. MSCs application proved therapeutic efficiency during influenza infection resulting in reduced impairment of alveolar fluid clearance and lung injury. This was attributed towards attenuation of pro-inflammatory cytokine secretion, inflammatory cell recruitment and increased alveolar macrophages content.

Aim of study:

1. To provide immune modulation to patients with COVID-19 who are taken to intensive care and resistant to treatment by performing MSCs transplantation and to reduce the damage caused by cytokin storm to tissues and organs,
2. Correcting immunosuppression in patients and increasing the fight against COVID-19 virus by CD4+T, CD+8T cellular cell arrangement,
3. It is to accelerate the recovery in organ damage by increasing growth factors by means of MSCs.

Materials and method:

Patients diagnosed with COVID-19 infection as clinically, radiologically and laboratory-wise will be divided into three groups:

Group 1: patients that are not on a ventilator (n=10) Group 2: patients that are on a ventilator and will receive saline injections (n=10) Group 3: patients that are on a ventilator and will receive MSC transplantation injections (n=10)

Mesenchymal stem cells originating from allogenic umbilical cord produced under GMP conditions will be administered in 3 times, with doses indicated below, intravenously within 1 week.

Dose:

1. Application: 3 million cells / kg IV ---------------------------------------- --------- 1 day
2. Application: 3 million cells / kg IV ---------------------------------------- --------- 3. Day
3. Application: 3 million cells / kg IV ---------------------------------------- --------- 6. Day

The blood will be analyzed for the expression levels of growth factors, including vascular endothelial growth factor, fibroblast growth factor, platelet derived-growth factor, epidermal growth factor, transforming growth factor beta, hepatocyte growth factor, nerve growth factor, VEGF receptor (VEGFR), angiopoietin1 (Angpt-1), and Angpt-2, using sandwich enzyme-linked immune sorbent assays (ELISAs). Investigators also analyzed the caspase-3 system in the blood. immunoassay kits will be used for analyses in accordance with the manufacturer's instructions.

Biochemical parameters of the liver, such as alanine transaminase (ALT), aspartate transaminase (AST), total protein, albumin, total bilirubin, direct bilirubin, and alkaline phosphatase (ALP) levels, will be measured in the venous blood samples.

Proinflammatory (IL1-β, IL-6, TNFα, INF-γ) and anti-inflammatory (IL-2, IL-4, IL-10, IL-13) cytokines will be examined in venous blood in order to determine the immune modulatory effect of stem cells. CD4 + T, CD4 + T killer cells Granulocyte macrophage colony factor BLC-2 VEGF-R angiopoetin-1, angiopoetin-2 Total antioxidant capacity (TAC) Total oxidant capacity (TOC).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Pneumonia Multiple Organ Failure Corona Virus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Untreated

Group 1: patients that are not on a ventilator (n=10) No extra intervention will be done.

Group Type NO_INTERVENTION

No interventions assigned to this group

Saline Control

Group 2: patients that are on a ventilator and will receive saline injections (n=10) as control for MSC transplantation group (3).

Group Type SHAM_COMPARATOR

Saline Control

Intervention Type BIOLOGICAL

Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.

Experimental UC-MSCs

Group 3: patients that are on a ventilator and will receive MSC transplantation injections (n=10)

Group Type EXPERIMENTAL

MSC Treatment

Intervention Type BIOLOGICAL

Protocol length: 1 week

Doses:

1. Application: 3 million cells/kg IV-------------------------------------------------0 day
2. Application: 3 million cells/kg IV ------------------------------------------------3rd day
3. Application: 3 million cells/kg IV -------------------------------------------------6th day

will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MSC Treatment

Protocol length: 1 week

Doses:

1. Application: 3 million cells/kg IV-------------------------------------------------0 day
2. Application: 3 million cells/kg IV ------------------------------------------------3rd day
3. Application: 3 million cells/kg IV -------------------------------------------------6th day

will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.

Intervention Type BIOLOGICAL

Saline Control

Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 40-60 years old male or female
* Confirmed 2019-nCoV infection with RT-PCR Laboratory test
* Confirmed Pneumonia with chest radiography and computer tomography
* and any of the following criteria:

1. Shortness of breath (RR ≥30/min)
2. Resting finger oxygen saturation 93%
3. Arterial oxygen partial pressure (PaO2)/oxygen absorption concentration (FiO2) ≤ 300MMHG
4. Advancing of focus in Pulmonary imaging to \>50% in 24-48 hours

Exclusion Criteria

* Those who are not pregnant, breastfeeding and pregnant but who do not take effective contraceptive measures;
* Patients with malignant tumors, other serious systemic diseases and psychosis;
* Informed consent is not given or does not comply with the test requirements.
* Co-infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory infection virus.
* Pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or co-infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory infection virus.
* Obstructive HABP / VABP caused by lung cancer or other known causes; Long-term history of use of immunosuppressive agents;
* History of epilepsy and need for continuous anticonvulsant therapy or anticonvulsant therapy taken within 3 years;
* Invasive ventilation
* Shock
* Other organ failures

Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No